-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Short Interest in Synaptogenix, Inc. (NASDAQ:SNPX) Increases By 24.8%
Short Interest in Synaptogenix, Inc. (NASDAQ:SNPX) Increases By 24.8%
Synaptogenix, Inc. (NASDAQ:SNPX – Get Rating) saw a significant growth in short interest in July. As of July 31st, there was short interest totalling 238,300 shares, a growth of 24.8% from the July 15th total of 190,900 shares. Based on an average daily trading volume, of 61,200 shares, the short-interest ratio is presently 3.9 days. Approximately 5.1% of the shares of the stock are sold short.
Institutional Trading of Synaptogenix
Large investors have recently bought and sold shares of the business. Orion Capital Management LLC acquired a new stake in Synaptogenix during the 4th quarter worth about $34,000. Renaissance Technologies LLC acquired a new stake in Synaptogenix during the 2nd quarter worth about $83,000. Finally, Vanguard Group Inc. grew its holdings in Synaptogenix by 248.9% during the 1st quarter. Vanguard Group Inc. now owns 216,836 shares of the company's stock worth $1,678,000 after acquiring an additional 154,688 shares during the period. 11.23% of the stock is currently owned by institutional investors and hedge funds.
Get Synaptogenix alerts:Synaptogenix Stock Up 5.1 %
Shares of NASDAQ:SNPX traded up $0.36 during trading on Friday, hitting $7.42. 145,902 shares of the company were exchanged, compared to its average volume of 99,143. Synaptogenix has a 1-year low of $3.79 and a 1-year high of $14.50. The business's 50 day moving average is $5.70 and its 200-day moving average is $6.31.
Synaptogenix (NASDAQ:SNPX – Get Rating) last posted its quarterly earnings data on Friday, May 13th. The company reported ($0.47) earnings per share for the quarter.About Synaptogenix
(Get Rating)
Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.
Featured Stories
- Get a free copy of the StockNews.com research report on Synaptogenix (SNPX)
- 2 Important Retail Stock Battles to Watch
- MarketBeat: Week in Review 8/8 – 8/12
- What Is WallStreetBets and What Stocks Are They Targeting?
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with MarketBeat.com's FREE daily email newsletter.
Synaptogenix, Inc. (NASDAQ:SNPX – Get Rating) saw a significant growth in short interest in July. As of July 31st, there was short interest totalling 238,300 shares, a growth of 24.8% from the July 15th total of 190,900 shares. Based on an average daily trading volume, of 61,200 shares, the short-interest ratio is presently 3.9 days. Approximately 5.1% of the shares of the stock are sold short.
新創公司(納斯達克代碼:SNPX-GET Rating)看到空頭股數在7月份實現了顯著增長。截至7月31日,空頭股數共有23.83萬股,比7月15日的19.99萬股增長24.8%。以日均成交量6.12萬股計算,目前短息比為3.9天。大約5.1%的股票被賣空。
Institutional Trading of Synaptogenix
Synaptogenix的制度性交易
Large investors have recently bought and sold shares of the business. Orion Capital Management LLC acquired a new stake in Synaptogenix during the 4th quarter worth about $34,000. Renaissance Technologies LLC acquired a new stake in Synaptogenix during the 2nd quarter worth about $83,000. Finally, Vanguard Group Inc. grew its holdings in Synaptogenix by 248.9% during the 1st quarter. Vanguard Group Inc. now owns 216,836 shares of the company's stock worth $1,678,000 after acquiring an additional 154,688 shares during the period. 11.23% of the stock is currently owned by institutional investors and hedge funds.
大型投資者最近買賣了該公司的股票。獵户座資本管理公司在第四季度收購了Synaptogenix的新股份,價值約3.4萬美元。復興科技有限公司在第二季度收購了Synaptogenix的新股份,價值約83,000美元。最後,先鋒集團在第一季度增持了248.9%的Synaptogenix股份。先鋒集團(Vanguard Group Inc.)在此期間增持了154,688股,目前持有216,836股該公司股票,價值1,678,000美元。該公司11.23%的股票目前由機構投資者和對衝基金持有。
Synaptogenix Stock Up 5.1 %
Synaptogenix股價上漲5.1%
Shares of NASDAQ:SNPX traded up $0.36 during trading on Friday, hitting $7.42. 145,902 shares of the company were exchanged, compared to its average volume of 99,143. Synaptogenix has a 1-year low of $3.79 and a 1-year high of $14.50. The business's 50 day moving average is $5.70 and its 200-day moving average is $6.31.
新浪納斯達克的股價在週五的交易中上漲了0.36美元,達到7.42美元。該公司股票成交量為145,902股,而其平均成交量為99,143股。Synaptogenix的一年低點為3.79美元,一年高位為14.50美元。該業務的50日移動均線切入位在5.70美元,200日移動均線切入位在6.31美元。
About Synaptogenix
關於Synaptogenix
(Get Rating)
(獲取評級)
Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.
Synaptogenix公司是一家生物製藥公司,在臨牀前和臨牀開發方面有候選產品。它專注於開發一個基於一種名為Bryostatin-1的候選藥物的產品平臺,用於治療阿爾茨海默病。該公司還在評估bryostatin在其他神經退行性或認知疾病和功能障礙方面的治療應用,如脆性X綜合徵、多發性硬化症和Niemann-Pick C型疾病。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Synaptogenix (SNPX)
- 2 Important Retail Stock Battles to Watch
- MarketBeat: Week in Review 8/8 – 8/12
- What Is WallStreetBets and What Stocks Are They Targeting?
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
- 免費獲取StockNews.com關於Synaptogenix的研究報告(SNPX)
- 值得關注的兩場重要的零售股大戰
- MarketBeat:回顧中的一週2012-8-8
- 什麼是WallStreetBets,他們的目標是什麼股票?
- 機構和分析師推動Jack in the Box走高
- 你能猜到哪個電動車股票打敗了特斯拉嗎?
Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with MarketBeat.com's FREE daily email newsletter.
接受Synaptogenix Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Synaptogenix和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧